Sign in with Google. Opens in new tab

Biopharma Week in Review - December 2, 2024

247 Views03 Dec 2024 00:10
Issuer-paid
The short holiday week saw another controversial name picked for NIH head, PSTX was acquired by RHHBY, AMGN underwhelmed with obesity data
What is covered in the Full Insight:
  • Introduction to Biopharma Events
  • Amgen's Obesity Data Analysis
  • Medicare's Obesity Drug Proposal
  • Sarepta and Arrowhead Asset Acquisition
  • Critical Regulatory Updates
SUMMARY
(Sign Up to Access)
Full Insight
(Paid Plans Only, 10-minute read)
Discussions
(Paid Plans Only)
chart-bar
  • Biopharma Week in Review - December 2, 2024
    03 Dec 2024
x